Effects of plasmalogen on mood and performance in university athletes

Not Applicable

• Conditions: Healthy persons

• Registration Number: JPRN-jRCTs071190028
• Lead Sponsor: Fujino Minoru

Brief Summary

Effects of plasmalogen (Pls) use for 4 weeks (2 mg per day) on POMS2, other psychological measures, and biological markers (blood Pls, plasma BDNF, urine 8-OHdG) were evaluated in a randomized placebo-controlled trial of 40 university athletes. The change in POMS2 TMD (primary outcome) did not show a statistically significant between-group difference. AH (anger-hostility) and FI (fatigue-inertia) of the POMS2 subscales showed greater decrease in Pls group than in placebo group (P <0.05).

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-10-08
• Study Completion: 2019-12-19
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 42

Inclusion Criteria

To meet all of the three conditions:
1) male students belonging to sport clubs of Kyushu Sangyo University;
2) unmarried men aged 18-22 years at the time of provision of informed consent; and
3) those who are able to provide wriiten informed consent.

Exclusion Criteria

To meet at least one of the following conditions:
1) those under medical treatment;
2) those who are participating in an other clinical trial;
3) those with shellfish allergy
4) those who are judged as ineligible by a principal physican investigator or a designated supervising investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
T score of the total distrubance of mood (TDM) score of the Profile of Mood State (POMS2).

Secondary Outcome Measures

Name	Time	Method
1) seven scales of POMS2;<br>2) Athene Insomnia Scale;<br>3) brain fatigue measurements including Brain-Fatigue Score Questionnaire and Kraepeline test;<br>4) exercise performance including VO2max, muscle strength, and power;<br>5) plasmalogens in plasma and erythrocytes;<br>6) blood concentrations of brain derived neurotrophic factor (BDNF) and adiponectin;<br>7) urinaruy 8-hydroxy deoxy quanine (8-OHdG);<br>8) body mass index and percent fat;<br>9) daily variation of mental and physical condition assessed by a smartphone application; and<br>10) 24-hour heart rate variation (those with a specified consent only).